BNP Paribas Easy EUR Corporate Bond SRI PAB UCITS ETF Dist (ASRT)

Overview

Assertio Holdings, Inc. is a commercial pharmaceutical company that targets the U.S. market by providing a diverse range of pharmaceutical products tailored to meet the needs of patients dealing with various conditions. The company, undergoing a name change from Assertio Therapeutics, Inc. to Assertio Holdings, Inc. in May 2020, has established its headquarters in Lake Forest, Illinois. Since its incorporation in 2020, Assertio Holdings has dedicated itself to advancing patient care by offering specialized pharmaceutical treatments aimed at improving the quality of life for those who suffer from chronic and acute conditions.

Products and Services

• INDOCIN:

  Available in both oral and suppository form, INDOCIN is designed to manage moderate to severe rheumatoid arthritis, addressing acute flares of the disease. It is also prescribed for ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis, providing relief and management of symptoms.

• Sympazan:

  A benzodiazepine formulation, Sympazan serves as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients aged two years or older. This medication aims to control seizures and enhance the quality of life for those affected by this specific type of epilepsy.

• CAMBIA:

  This non-steroidal anti-inflammatory drug (NSAID) is specifically formulated to treat migraine pain and its associated symptoms, including nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound), offering relief to migraine sufferers.

• Zipsor:

  As a NSAID, Zipsor is prescribed for the relief of mild to moderate acute pain in adults. The medication provides effective pain management for a range of conditions, enabling patients to experience relief from discomfort.

• SPRIX:

  SPRIX is another NSAID in the Assertio portfolio, but it is indicated for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level, allowing for an alternative pain management solution.

• Otrexup:

  Otrexup combines the functionality of a single-dose auto-injector with a prescription medication, methotrexate, to treat severe, active rheumatoid arthritis, active polyarticular juvenile idiopathic arthritis, and adults with severe, recalcitrant, disabling psoriasis, offering a more manageable treatment option.

• ROLVEDON:

  ROLVEDON, a long-acting granulocyte colony-stimulating factor, is specifically indicated to decrease the incidence of infection as manifested by febrile neutropenia. This medication aims to prevent infections in patients with compromised immune systems due to treatment regimens.